Lupin: The pharma company reported a 52% YoY increase in consolidated net profit, amounting to ₹359.43 crore, for Q4 FY24. Its revenue rose by 13% from the previous year to ₹4,895.11 crore. EBITDA for the quarter was ₹1,026.1 crore, a 66% increase from ₹615 crore in the same period last year.
The EBITDA margin was 14.2%, compared to 11.5% in the year-ago period. However, Profit Before Tax was lower due to an impairment charge of ₹201.3 crore. The company invested ₹425.5 crore (8.7% of sales) in R&D for the quarter.
US sales accounted for 39% of Lupin’s global sales, with Q4FY24 sales amounting to ₹1,900.6 crore, a 0.6% increase from Q3FY24 and a 22.6% increase from Q4FY23. Sales in India accounted for 33% of Lupin’s global sales, with Q4FY24 sales amounting to ₹1,601.5 crore, a 7.2% decrease from Q3FY24 but an 8.3% increase from Q4FY23. Global API sales accounted for 5% of Lupin’s global sales, with Q4FY24 sales amounting to ₹258.1 crore, a 7.1% decrease from Q3FY24 and a 20% decrease from Q4FY23.
Godrej Consumer Products: GCPL reported a net loss of ₹1,893.2 crore for Q4 FY24, compared to a net profit of ₹452 crore in the same period last year. The company's revenue from operations increased by 5.8% to ₹3,385.6 crore. EBITDA rose by 17.9% to ₹755.7 crore, and the EBITDA margin stood at 22.3%, compared to 20% in the corresponding period in the previous fiscal.
The board has declared an interim dividend of ₹10 per share (1,000% on shares of face value of ₹1 each) for the financial year 2024-25. Gujarat Fluorochemicals: GFL reported a 69.6% YoY decrease in net profit, amounting to ₹101 crore, for Q4FY24. The company's revenue also fell by 23% to ₹1,133 crore.
Read more on livemint.com